Advancing Precision-Targeted Treatment for Patients With Metastatic Non-Small Cell Lung Cancer

Area of Science:

• Oncology
• Pharmacology
• Clinical Medicine

Background:

• Metastatic non-small cell lung cancer (NSCLC) treatment has advanced with molecular targeted and combination therapies.
• Biomarker testing is crucial for identifying patients who may benefit from these novel treatments.

Purpose of the Study:

• To review the implications of biomarker testing in NSCLC.
• To discuss pivotal clinical trials supporting recent FDA approvals for NSCLC therapies.
• To outline evidence-based best practices for managing adverse events associated with these treatments.

Main Methods:

• The content is based on discussions from JADPRO Live 2023.
• Key topics included biomarker testing, clinical trial data, and adverse event management.

Main Results:

• Biomarker testing guides therapeutic decisions in metastatic NSCLC.
• Recent FDA approvals have expanded treatment options.
• Effective monitoring and management of adverse events are essential for patient safety and treatment adherence.

Conclusions:

• Integrating biomarker testing and understanding clinical trial outcomes are vital for optimizing NSCLC care.
• Adherence to best practices in adverse event management improves patient outcomes with advanced therapies.